Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$129.0M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
895.01%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$359.4M
Q3 2024
Cash
Q3 2024
P/E
-3.189
Dec 02, 2024 EST
Free Cash Flow
-$96.59M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022
Revenue $50.00M $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022
Revenue $50.00M $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022
Selling, General & Admin $17.11M $13.51M
YoY Change 26.68%
% of Gross Profit
Research & Development $60.03M $61.69M
YoY Change -2.68%
% of Gross Profit
Depreciation & Amortization $113.0K $78.00K
YoY Change 44.87%
% of Gross Profit
Operating Expenses $77.15M $75.20M
YoY Change 2.59%
Operating Profit
YoY Change

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $324.0K -$43.08M
YoY Change -100.75%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022
Pretax Income -$36.82M -$119.3M
YoY Change -69.13%
Income Tax $301.0K $0.00
% Of Pretax Income
Net Earnings -$37.12M -$119.3M
YoY Change -68.88%
Net Earnings / Revenue -74.25%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.93 -$3.00

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022
Cash & Short-Term Investments $56.86M $67.21M
YoY Change -15.4%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $2.947M $1.235M
YoY Change 138.62%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $59.80M $68.44M
YoY Change -12.62%
Property, Plant & Equipment $1.014M $1.801M
YoY Change -43.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.362M $4.334M
YoY Change 69.87%
Total Long-Term Assets $8.376M $6.135M
YoY Change 36.53%
Total Assets $68.18M $74.58M
YoY Change
Accounts Payable $5.396M $5.815M
YoY Change -7.21%
Accrued Expenses $17.46M $20.05M
YoY Change -12.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.26M $25.97M
YoY Change -10.43%
Long-Term Debt $20.30M $0.00
YoY Change
Other Long-Term Liabilities $257.0K $812.0K
YoY Change -68.35%
Total Long-Term Liabilities $20.56M $812.0K
YoY Change 2431.65%
Total Liabilities $43.82M $26.78M
YoY Change 63.62%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $411.22 Million

About Zenas BioPharma, Inc.

Zenas Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Waltham, Massachusetts and currently employs 115 full-time employees. The company went IPO on 2024-09-13. Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is focused on the development and commercialization of immunology-based therapies for patients in need. Its lead immunology and inflammation (I&I) product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The company is developing obexelimab as a potential I&I franchise for patients in several autoimmune diseases. Its pipeline also includes two global programs, ZB002 (an anti-TNFα monoclonal antibody) and ZB004 (a CTLA-4-Ig fusion), and two regional programs, ZB001 (also known as VRDN-001, an IGF-1R monoclonal antibody), and related programs, and ZB005 (also known as DNTH103, an anti-active C1s monoclonal antibody), for which the Company hold the development and commercialization rights in greater China.

Industry: Pharmaceutical Preparations Peers: